Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malignant Melanoma

  Free Subscription


Articles published in J Immunother

Retrieve available abstracts of 39 articles:
HTML format
Text format



Single Articles


    June 2019
  1. KHOURY ZH, Hausner PF, Idzik-Starr CL, Frykenberg MRA, et al
    Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature.
    J Immunother. 2019 Jun 14. doi: 10.1097/CJI.0000000000000282.
    PubMed     Text format     Abstract available


  2. LESAGE C, Longvert C, Prey S, Maanaoui S, et al
    Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
    J Immunother. 2019;42:175-179.
    PubMed     Text format     Abstract available


    May 2019
  3. BISSCHOP C, Wind TT, Blank CU, Koornstra RHT, et al
    Association Between Pembrolizumab-related Adverse Events and Treatment Outcome in Advanced Melanoma: Results From the Dutch Expanded Access Program.
    J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000271.
    PubMed     Text format     Abstract available


  4. GAMBICHLER T, Schroter U, Hoxtermann S, Susok L, et al
    A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000277.
    PubMed     Text format     Abstract available


  5. AFZAL MZ, Sarwar T, Shirai K
    Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors.
    J Immunother. 2019 May 28. doi: 10.1097/CJI.0000000000000272.
    PubMed     Text format     Abstract available


  6. LESAGE C, Longvert C, Prey S, Maanaoui S, et al
    Incidence and Clinical Impact of Anti-TNFalpha Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.
    J Immunother. 2019 May 15. doi: 10.1097/CJI.0000000000000268.
    PubMed     Text format     Abstract available


    April 2019
  7. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Racial and Socioeconomic Disparities in the Delivery of Immunotherapy for Metastatic Melanoma in the United States.
    J Immunother. 2019 Apr 10. doi: 10.1097/CJI.0000000000000264.
    PubMed     Text format     Abstract available


    March 2019
  8. AFZAL MZ, Shirai K
    Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    J Immunother. 2019 Mar 29. doi: 10.1097/CJI.0000000000000265.
    PubMed     Text format     Abstract available


  9. DAVIS EJ, Perez MC, Ayoubi N, Zhao S, et al
    Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma.
    J Immunother. 2019 Mar 13. doi: 10.1097/CJI.0000000000000258.
    PubMed     Text format     Abstract available


    February 2019
  10. DIEM S, Fassler M, Bomze D, Ali OH, et al
    Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.
    J Immunother. 2019 Feb 13. doi: 10.1097/CJI.0000000000000255.
    PubMed     Text format     Abstract available


    November 2018
  11. LINDENBERG MA, Retel VP, van den Berg JH, Geukes Foppen MH, et al
    Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product.
    J Immunother. 2018;41:413-425.
    PubMed     Text format     Abstract available


    July 2018
  12. ZHENG F, Dang J, Zhang H, Xu F, et al
    Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
    J Immunother. 2018 Jul 30. doi: 10.1097/CJI.0000000000000242.
    PubMed     Text format     Abstract available


    June 2018
  13. DIMITRIOU F, Matter AV, Mangana J, Urosevic-Maiwald M, et al
    Cytokine Release Syndrome During Sequential Treatment With Immune Checkpoint Inhibitors and Kinase Inhibitors for Metastatic Melanoma.
    J Immunother. 2018 Jun 22. doi: 10.1097/CJI.0000000000000236.
    PubMed     Text format     Abstract available


  14. ZHAO CY, Hwang SJE, Anforth R, Carlos G, et al
    Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
    J Immunother. 2018 Jun 22. doi: 10.1097/CJI.0000000000000237.
    PubMed     Text format     Abstract available


    May 2018
  15. TAVERA RJ, Forget MA, Kim YU, Sakellariou-Thompson D, et al
    Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
    J Immunother. 2018 May 11. doi: 10.1097/CJI.0000000000000230.
    PubMed     Text format     Abstract available


    April 2018
  16. MEHTA GU, Malekzadeh P, Shelton T, White DE, et al
    Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
    J Immunother. 2018 Apr 18. doi: 10.1097/CJI.0000000000000223.
    PubMed     Text format     Abstract available


    February 2018
  17. TANDON P, Bourassa-Blanchette S, Bishay K, Parlow S, et al
    The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis.
    J Immunother. 2018 Feb 2. doi: 10.1097/CJI.0000000000000213.
    PubMed     Text format     Abstract available


    January 2018
  18. GORDY JT, Luo K, Francica B, Drake C, et al
    Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3alpha-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
    J Immunother. 2018 Jan 12. doi: 10.1097/CJI.0000000000000212.
    PubMed     Text format     Abstract available


  19. ANASTASOPOULOU A, Papaxoinis G, Diamantopoulos P, Christofidou E, et al
    Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.
    J Immunother. 2018 Jan 5. doi: 10.1097/CJI.0000000000000210.
    PubMed     Text format     Abstract available


  20. SUN Y, Lee SK, Oo TH, Rojas-Hernandez CM, et al
    Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases.
    J Immunother. 2018;41:32-34.
    PubMed     Text format     Abstract available


  21. TAJMIR-RIAHI A, Bergmann T, Schmid M, Agaimy A, et al
    Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy.
    J Immunother. 2018;41:35-38.
    PubMed     Text format     Abstract available


    December 2017
  22. COWEY CL, Liu FX, Black-Shinn J, Stevinson K, et al
    Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
    J Immunother. 2017 Dec 15. doi: 10.1097/CJI.0000000000000204.
    PubMed     Text format     Abstract available


    September 2017
  23. ZECCHINI JM, Kim S, Yum K, Friedlander P, et al
    Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.
    J Immunother. 2017 Sep 18. doi: 10.1097/CJI.0000000000000184.
    PubMed     Text format     Abstract available


    July 2017
  24. REDDY SB, Possick JD, Kluger HM, Galan A, et al
    Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma.
    J Immunother. 2017 Jul 21. doi: 10.1097/CJI.0000000000000181.
    PubMed     Text format     Abstract available


    June 2017
  25. PUSHKAREVSKAYA A, Neuberger U, Dimitrakopoulou-Strauss A, Enk A, et al
    Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases.
    J Immunother. 2017 Jun 9. doi: 10.1097/CJI.0000000000000178.
    PubMed     Text format     Abstract available


  26. KELLY WU W, Broman KK, Brownie ER, Kauffmann RM, et al
    Ipilimumab-induced Guillain-Barre Syndrome Presenting as Dysautonomia: An Unusual Presentation of a Rare Complication of Immunotherapy.
    J Immunother. 2017;40:196-199.
    PubMed     Text format     Abstract available


  27. YU G, Moudgil T, Cui Z, Mou Y, et al
    Ubiquitinated Proteins Isolated From Tumor Cells Are Efficient Substrates for Antigen Cross-Presentation.
    J Immunother. 2017;40:155-163.
    PubMed     Text format     Abstract available


    May 2017
  28. DIAMANTOPOULOS PT, Tsatsou K, Benopoulou O, Anastasopoulou A, et al
    Inflammatory Myopathy and Axonal Neuropathy in a Patient With Melanoma Following Pembrolizumab Treatment.
    J Immunother. 2017 May 11. doi: 10.1097/CJI.0000000000000172.
    PubMed     Text format     Abstract available


    February 2017
  29. DAGOGO-JACK I, Lanfranchi M, Gainor JF, Giobbie-Hurder A, et al
    A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis.
    J Immunother. 2017 Feb 17. doi: 10.1097/CJI.0000000000000159.
    PubMed     Text format     Abstract available


  30. BRICOUT M, Petre A, Amini-Adle M, Bezza W, et al
    Vogt-Koyanagi-Harada-like Syndrome Complicating Pembrolizumab Treatment for Metastatic Melanoma.
    J Immunother. 2017;40:77-82.
    PubMed     Text format     Abstract available


    January 2017
  31. DAY F, Kumar M, Fenton L, Gedye C, et al
    Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    J Immunother. 2017;40:36-38.
    PubMed     Text format     Abstract available


    November 2016
  32. BRIGHT R, Coventry BJ, Eardley-Harris N, Briggs N, et al
    Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years' Experience: A Meta-Analysis of 3312 Patients.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  33. JOHNSON DB, Pectasides E, Feld E, Ye F, et al
    Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  34. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients.
    J Immunother. 2016;39:355-366.
    PubMed     Text format     Abstract available


  35. TAHTINEN S, Blattner C, Vaha-Koskela M, Saha D, et al
    T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFalpha Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    J Immunother. 2016;39:343-354.
    PubMed     Text format     Abstract available


    September 2016
  36. MA Q, Zhou D, DeLyria ES, Wen X, et al
    Synthetic Poly(L-Glutamic Acid)-conjugated CpG Exhibits Antitumor Efficacy With Increased Retention in Tumor and Draining Lymph Nodes After Intratumoral Injection in a Mouse Model of Melanoma.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  37. DIEM S, Keller F, Ruesch R, Maillard SA, et al
    Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?
    J Immunother. 2016.
    PubMed     Text format     Abstract available


  38. KROPP LM, De Los Santos JF, McKee SB, Conry RM, et al
    Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
    J Immunother. 2016.
    PubMed     Text format     Abstract available


    January 2016
  39. PARK TS, Groh EM, Patel K, Kerkar SP, et al
    Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers.
    J Immunother. 2016;39:1-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: